Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»Business

    ‘Miracle drug’ euphoria: Experts warn widespread use of weight loss medicine faces major hurdles

    AdminBy AdminOctober 15, 2023 Business
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    In this article

    • LLY
    • NOVO.B-DK

    Two experts see major challenges facing the adoption of new obesity drugs.

    Dr. Kavita Patel, a physician and NBC News medical contributor, believes fresh data from Novo Nordisk on Ozempic’s ability to delay the progression of chronic kidney disease is among the strongest supporting evidence for secondary uses of the drug.

    However, she considers data supporting the use of obesity drugs for other conditions including Alzheimer’s and alcohol addiction as underdeveloped.

    “Those trials … are nowhere near as robust as the data we have on [Novo Nordisk trial] FLOW, on sleep apnea, cardiovascular risks, on diabetes control — double-blind placebo, randomized controlled trials that are incredible,” she told CNBC’s “Fast Money” on Wednesday. “We have a long way to go for that. I’ve seen a lot of miracle drugs before.”

    Novo Nordisk halted FLOW on Tuesday. According to the company’s press release, it happened more than a year after an interim analysis showed that Ozempic could treat chronic kidney disease in Type 2 diabetic patients.

    As of Friday’s close, Novo Nordisk is up 9.82% since its announcement. Its obesity drug maker competitor Eli Lilly is up 5.16% in the same period.

    Patel believes efficacy is just one of the major hurdles the medication needs to clear before it can be approved for uses outside of diabetes management.

    “We know this drug works really well in diabetics. But there are so many barriers to getting there —including cost, adherence, prescriber rate,” said Patel, who also served as a White House Health Policy Director under President Obama.

    Patients opting to use GLP-1 drugs — a group of medications initially designed to control diabetes — for weight management often must pay out-of-pocket.

    “Right now, we are seeing active employers, entire states that are declining to cover on the weight loss indication,” Patel said.

    If the U.S. Food and Drug Administration approves Ozempic for use in Type 2 diabetics with chronic kidney disease, which Patel believes will happen, it could force the hand of insurance companies to expand their coverage of the drug.

    “We’ll see a final package of data that will just be so compelling, that it would be wrong not to cover this, because it should be superior to what we have available to us,” she noted. “That is something that I think the insurance companies will have a difficult time [with].”

    Mizuho Health Care Sector Strategist Jared Holz also expects challenges related to insurance coverage as more patients begin taking GLP-1 drugs, which could limit overall adoption.

    “The payers, at some point, are going to be saying, ‘We get it, but we cannot pay for these at this volume without seeing the benefit, which may be 10 years from now, 20 years from now, 30.’ We have no idea when the offset is going to be,” he also told CNBC’s “Fast Money.”

    Holz also pointed out the divide emerging in the health care sector between Novo Nordisk, Eli Lilly and their pharmaceutical peers.

    “We haven’t seen this kind of valuation disconnect between the peer group, maybe in the history of the sector,” he said.

    The growth trend may not be sustainable for Novo Nordisk and Eli Lilly, based on current supply constraints that have left patients unable to secure dosages.

    “The companies can’t make enough, I don’t think, to actually put out revenue that’s going to appease investors, given where the stocks are trading,” said Holz.

    A Novo Nordisk spokesperson did not offer a comment due to the company’s quiet period ahead of earnings. Eli Lilly did not immediately respond to a request for comment.

    Disclaimer
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Anthropic prices IPO at $83 a share, blowing past target range: report

    November 19, 2026

    California DMV boots Waymo robotaxis off state freeways after string of incidents

    November 18, 2026

    Chipotle launches Sneak It In hoodies with hidden pouch to keep your burrito warm

    November 17, 2026

    Big-ticket holiday items may be harder to find as shipping costs rise

    November 16, 2026

    Jensen Huang weighs Nvidia CEO comeback as ally plans war room: report

    November 16, 2026

    New Orleans port seeks tanker seizure after cruise ship crash sparks $1M lawsuit

    November 15, 2026
    Popular Posts

    How to tell a cyberattack from a plain old outage

    Movie Review: Elsinore

    Interview with Aletheia von Gottlieb, Author of Love Off the Ice (Sweet Snowfall Kisses Book 1) – NewInBooks

    What Were Wearing: Friendsgiving

    In historic move, House Democrats nominate Hakeem Jeffries for speaker of the House

    Book Riots Deals of the Day for November 18, 2026

    Categories
    • Books (2,457)
    • Business (3,449)
    • Events (34)
    • Film (1,062)
    • LifeStyle (2,922)
    • Music (2,796)
    • Politics (2,355)
    • Science (1,952)
    • Technology (1,817)
    • Television (3,628)
    • US News (3,294)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Catherine Phipps – ‘Seeing an aircraft take off and knowing you contributed to the engine design is an amazing feeling’ – Physics WorldCatherine Phipps – ‘Seeing an aircraft take off and knowing you contributed to the engine design is an amazing feeling’ – Physics World
    • Iran launches missile attack on Israel for Nasrallah killingIran launches missile attack on Israel for Nasrallah killing
    • Tropical storms like Alberto can lead to years of declining incomesTropical storms like Alberto can lead to years of declining incomes
    • Secret Lives of Mormon Wives Sets Season 3 Premiere Date for NovemberSecret Lives of Mormon Wives Sets Season 3 Premiere Date for November
    • Megyn Kelly Says Jimmy Kimmel Panicking Over ‘Job Security’Megyn Kelly Says Jimmy Kimmel Panicking Over ‘Job Security’
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.